CHENGDU, China, June 28 TianyinPharmaceutical (NYSE Amex: TPI), a biopharmaceutical company that specializesin patented biopharmaceutical, modernized traditional Chinese medicine andbranded generics will exhibit and promote its flagship product portfolio atthe 45th 2010 National New Special Drugs Trade Fair at Beijing NationalConvention Center from July 8th, till July 10th. Tianyin's portfolio isfeatured by the patented Ginkgo Mihuan Oral Liquid (GMOL) for cardiovascularand central nervous system indications, Apu Shuangxin (APU, BenorylateGranules) for fever, inflammation and rheumatism, Xuelian Chongcao OralSolution (XLCC) for heart diseases, asthma and gynecological conditions, alongwith other prescription medicines that target high incidence China health careindications.
"Years of sales and marketing efforts by Tianyin Pharmaceutical haveestablished a nationwide network that covers more than 850 hospitals with anin-depth market penetration," said Dr. Jiang, Guoqing. "The network synergizeswith our marketing strategies that target high incidence, chronic conditionsin a growing aging Chinese population whose health care spending is boosted byan increasing disposable income and health care funding by the government.This synergy is centered on our flagship portfolio such as GMOL, APU, and XLCCetc. that contributes close to 50% of our annual revenue."
About National New Special Drugs Trade Fair
The 45th National New Special Drugs Trade Fair gathers the leadingpharmaceutical enterprises, elite new drug R&D institutes, the technologytransfer organizations, and the biomedical science and technology industrialareas in China to offer a platform for both scientific and commercialcollaboration and development. An International new medicine technologytransfer and the commercialization collaboration summit will be conducted withthe main Trade Fair.
About Tianyin Pharmaceutical
Tianyin Pharmaceutical Co., Inc., headquartered in Chengdu, SichuanProvince of China, is a leading biopharmaceutical company that specializes inthe development, manufacturing, marketing and sale of modernized traditionalChinese medicines and branded generics. Tianyin is equipped with two state-of-the-art manufacturing facilities and an extensive nationwide sales anddistribution network throughout China. Tianyin currently manufactures andmarkets a comprehensive portfolio of 56 products, of which 23 are listed inthe highly selective National Medicine Catalog of the National MedicalInsurance program, 7 are included in the essential drug list of China. Tianyinhas an extensive nationwide distribution network with a sales force of 720sales representatives out of totaled 1,365 employees. For more informationabout Tianyin, please visit http://www.tianyinpharma.com .
Safe Harbor Statement
The Statements which are not historical facts contained in this pressrelease are forward-looking statements that involve certain risks anduncertainties including but not limited to risks associated with theuncertainty of future financial results, additional financing requirements,development of new products, government approval processes, the impact ofcompetitive products or pricing, technological changes, the effect of economicconditions and other uncertainties detailed in the Company's filings with theSecurities and Exchange Commission.For more information, please contact: Tianyin Pharmaceutical Co., Inc. James Jiayuan Tong M.D. Ph.D. Chief Financial Officer, Chief Business & Development Officer Director 23rd Floor Unionsun Yangkuo Plaza No. 2, Block 3, South Renmin Road Chengdu, 610041 China Web: http://www.tianyinpharma.com Email: Dr.Tong@tianyinpharma.com Tel: +86-28-8551-6696 (Chengdu, China) +86-134-3655-0011 +1-949-350-6999 (U.S.)
SOURCE Tianyin Pharmaceutical Co., Inc.